S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10

Athersys Stock Forecast, Price & News

-0.02 (-1.59 %)
(As of 10/22/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume914,815 shs
Average Volume2.12 million shs
Market Capitalization$280.56 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ATHX News and Ratings via Email

Sign-up to receive the latest news and ratings for Athersys and its competitors with MarketBeat's FREE daily newsletter.

Athersys logo

About Athersys

Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$1.44 million
Book Value
$0.16 per share


Net Income
$-78.76 million




Market Cap
$280.56 million
Next Earnings Date
11/15/2021 (Confirmed)

Social Links


Overall MarketRank

2.06 out of 5 stars

Medical Sector

499th out of 1,359 stocks

Pharmaceutical Preparations Industry

233rd out of 666 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Athersys (NASDAQ:ATHX) Frequently Asked Questions

Is Athersys a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athersys in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Athersys stock.
View analyst ratings for Athersys
or view top-rated stocks.

What stocks does MarketBeat like better than Athersys?

Wall Street analysts have given Athersys a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Athersys wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Athersys' next earnings date?

Athersys is scheduled to release its next quarterly earnings announcement on Monday, November 15th 2021.
View our earnings forecast for Athersys

How can I listen to Athersys' earnings call?

Athersys will be holding an earnings conference call on Monday, November 15th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 416-621-4642 with passcode "6652068".

How were Athersys' earnings last quarter?

Athersys, Inc. (NASDAQ:ATHX) released its earnings results on Sunday, August, 8th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.10).
View Athersys' earnings history

How has Athersys' stock price been impacted by COVID-19 (Coronavirus)?

Athersys' stock was trading at $1.28 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ATHX stock has decreased by 3.1% and is now trading at $1.24.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ATHX?

1 brokerages have issued 1-year target prices for Athersys' shares. Their forecasts range from $5.00 to $5.00. On average, they anticipate Athersys' stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 303.2% from the stock's current price.
View analysts' price targets for Athersys
or view top-rated stocks among Wall Street analysts.

Who are Athersys' key executives?

Athersys' management team includes the following people:
  • William B. J. Lehmann, President, Chief Executive & Operating Officer (LinkedIn Profile)
  • Ivor MacLeod, Chief Financial & Accounting Officer
  • John J. Harrington, Director, Chief Scientific Officer & Executive VP (LinkedIn Profile)
  • Rakesh Ramachandran, Head-Information Technology & Communications
  • Eric Jenkins, Senior Director-Medical & Head-Clinical Operations

What is Gil Van Bokkelen's approval rating as Athersys' CEO?

2 employees have rated Athersys CEO Gil Van Bokkelen on Glassdoor.com. Gil Van Bokkelen has an approval rating of 100% among Athersys' employees. This puts Gil Van Bokkelen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Athersys own?

What is Athersys' stock symbol?

Athersys trades on the NASDAQ under the ticker symbol "ATHX."

Who are Athersys' major shareholders?

Athersys' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include NEXT Financial Group Inc (0.11%), Green Alpha Advisors LLC (0.08%), Livingston Group Asset Management CO operating as Southport Capital Management (0.02%) and Private Advisor Group LLC (0.01%). Company insiders that own Athersys stock include John J Harrington, John J Harrington, Kenneth H Traub, Laura K Campbell and William Lehmann Jr.
View institutional ownership trends for Athersys

Which major investors are selling Athersys stock?

ATHX stock was sold by a variety of institutional investors in the last quarter, including Livingston Group Asset Management CO operating as Southport Capital Management , and NEXT Financial Group Inc. Company insiders that have sold Athersys company stock in the last year include John J Harrington, Laura K Campbell, and William Lehmann Jr.
View insider buying and selling activity for Athersys
or view top insider-selling stocks.

Which major investors are buying Athersys stock?

ATHX stock was acquired by a variety of institutional investors in the last quarter, including Private Advisor Group LLC, and Green Alpha Advisors LLC.
View insider buying and selling activity for Athersys
or or view top insider-buying stocks.

How do I buy shares of Athersys?

Shares of ATHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Athersys' stock price today?

One share of ATHX stock can currently be purchased for approximately $1.24.

How much money does Athersys make?

Athersys has a market capitalization of $280.56 million and generates $1.44 million in revenue each year. The biopharmaceutical company earns $-78.76 million in net income (profit) each year or ($0.42) on an earnings per share basis.

How many employees does Athersys have?

Athersys employs 97 workers across the globe.

When was Athersys founded?

Athersys was founded in 1995.

What is Athersys' official website?

The official website for Athersys is www.athersys.com.

Where are Athersys' headquarters?

Athersys is headquartered at 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115.

How can I contact Athersys?

Athersys' mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The biopharmaceutical company can be reached via phone at (216) 431-9900 or via email at [email protected].

This page was last updated on 10/23/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.